Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

This study has been completed.

Sponsor:

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT00304629

First received: March 17, 2006

Last updated: January 31, 2011

Last verified: January 2011

History of Changes

Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	March 2002
Estimated Primary Completion Date:	No date given

No publications provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry. 2008 Feb;23(2):207-14.

To Top